Subscribe
shutterstock_2055997766_michael_vi
Michael Vi / Shutterstock.com
25 May 2023Big PharmaLiz Hockley

J&J settles Amgen clash over blockbuster psoriasis drug

Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
J&J hit with suit over Neutrogena products
20 April 2023   Canadian firm alleges infringement of patent directed to cosmetic and pharmaceutical formulations | Pharma giant declined a licensing agreement.
Americas
Eye care company settles with J&J Surgical Vision for $199m
13 February 2023   J&J had accused defendant of infringing patents related to cataract surgery | Company also complained its copyright-protected computer programs had been ripped off, alleging “piracy of a nearly unfathomable scale”.
article
J&J awarded $18m in fake surgical devices case
27 July 2023   Judge enters default judgment and permanent injunction order after defendant failed to show in court | Alleged counterfeit medical tools were being sold under Ethicon brand.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
J&J hit with suit over Neutrogena products
20 April 2023   Canadian firm alleges infringement of patent directed to cosmetic and pharmaceutical formulations | Pharma giant declined a licensing agreement.
Americas
Eye care company settles with J&J Surgical Vision for $199m
13 February 2023   J&J had accused defendant of infringing patents related to cataract surgery | Company also complained its copyright-protected computer programs had been ripped off, alleging “piracy of a nearly unfathomable scale”.
article
J&J awarded $18m in fake surgical devices case
27 July 2023   Judge enters default judgment and permanent injunction order after defendant failed to show in court | Alleged counterfeit medical tools were being sold under Ethicon brand.

More on this story

Big Pharma
J&J hit with suit over Neutrogena products
20 April 2023   Canadian firm alleges infringement of patent directed to cosmetic and pharmaceutical formulations | Pharma giant declined a licensing agreement.
Americas
Eye care company settles with J&J Surgical Vision for $199m
13 February 2023   J&J had accused defendant of infringing patents related to cataract surgery | Company also complained its copyright-protected computer programs had been ripped off, alleging “piracy of a nearly unfathomable scale”.
article
J&J awarded $18m in fake surgical devices case
27 July 2023   Judge enters default judgment and permanent injunction order after defendant failed to show in court | Alleged counterfeit medical tools were being sold under Ethicon brand.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent